Natalie Callander, MD, details findings from her study, evaluating the impact of quadruplet therapy on newly diagnosed patients with high-risk multiple myeloma.
Case: A 61-Year-Old Woman with Transplant-Preferred Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Presentation:
Clinical Workup and Diagnosis:
Current Treatment:
Transcript:
Natalie Callander, MD: I was very happy to be the head of a group composed of GRIFFIN and MASTER investigators. We pooled our data to see the impact of these quadruplet regimens on the outcome of patients with high-risk cytogenetics. We found out that in both studies there were somewhat more high-risk patients in the MASTER trial because it was amended to enrich for those patients. In both studies, the high-risk patients—those who had 2 or more high-risk cytogenetic abnormalities—were benefiting but at a lower rate.
Initially, their MRD [minimal residual disease]–negativity rate was fine, but we got there. Over time, they had a deterioration. With a several-year follow-up, we were seeing that only 60% of patients in both studies were remaining MRD negative. Both were consistent in 2 different approaches with these quadruplet regimens, but they signal that we need to do more for patients with 2 or more cytogenic abnormalities, either in the induction part or more likely in the maintenance phase—perhaps the addition of longer therapy or more or novel drugs in that area.
Transcript edited for clarity.
IKEMA Shows Advantage for Anti-CD38 in 1q21+ R/R Multiple Myeloma
March 22nd 2024During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series
Read More
Enhancing Outcomes in Myeloma With CAR T Cells and Bispecific Antibodies
March 18th 2024March is Multiple Myeloma Awareness Month and experts like Amrita Krishnan, MD, and Adam D. Cohen, MD, explained the positive impact CAR T-cell therapies and bispecific antibodies have had in the space.
Read More
FDA’s ODAC Finds Cilta-Cel Favorable in R/R Multiple Myeloma
March 15th 2024During an Oncologic Drug Advisory Committee Meeting, the FDA found that ciltacabtagene autoleucel has a favorable benefit/risk profile in relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy and are refractory to lenalidomide.
Read More